FIELD: medicine, pharmacology, pharmacy. SUBSTANCE: invention relates to preparing interferon- -containing compositions that are able to retain their biological activity and can be used as drugs for intranasal using, for example, for nasal drops making. Antiviral agent that is nasal drops has alpha-, beta- or gamma-interferon prepared by methods of genetic engineering with viscosity value (1.1-30.0) x 10 Pa x s, biologically compatible polymer, antioxidant, ridostin and buffer mixture. Ridostin content in the claimed agent is 0.00001-100.0 mg/1 ml of buffer mixture. Agent provides good absorption, optimal viscosity and distribution on surface of mucosa tissue with prolonged retention. EFFECT: enhanced effectiveness of antiviral agent. 3 ex
Title | Year | Author | Number |
---|---|---|---|
ANTIVIRAL MEDICATION - NASAL DROPS | 2010 |
|
RU2437676C1 |
ANTIVIRAL AGENT - NASAL DROPS "GRIPPFERON" | 1999 |
|
RU2140285C1 |
CYTOKINE-CONTAINING MEDICATION, POSSESSING ANTIVIRAL, ANTIMICROBIAL, IMMUNOMODULATING AND ANTI-INFLAMMATORY ACTION FOR PREVENTION AND TREATMENT OF INFECTION DISEASES | 2013 |
|
RU2554495C2 |
INTRANASAL AGENT | 2002 |
|
RU2220739C1 |
ANTIVIRAL AGENT - EYE DROPS | 2012 |
|
RU2473363C1 |
ANTIVIRAL AGENT | 2000 |
|
RU2187330C1 |
ANTIVIRAL AGENT - EYE DROPS "OFTALMOFERON" | 1999 |
|
RU2140286C1 |
CONDOM LUBRICANT | 2000 |
|
RU2187329C1 |
CURATIVE AGENT | 2000 |
|
RU2187332C1 |
OPHTHALMIC DROPS FOR TREATMENT OF INFLAMMATORY EYE DISEASE WITH ALLERGIC SYMPTOMS | 2000 |
|
RU2156128C1 |
Authors
Dates
2001-01-27—Published
2000-04-13—Filed